Du är här

2014-05-14

Sunshine Heart, Inc.: Sunshine Heart Announces Presentations at the Annual Meeting of the Heart Failure Association (HFA) of the European Society of Cardiology

EDEN PRAIRIE, Minn., May 14, 2014 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc.
(Nasdaq:SSH) today announced that Dr. Patrick Verta, Sunshine Heart's Chief
Medical Officer, will be presenting two posters at the Annual Meeting of the
Heart Failure Association (HFA) of the European Society of Cardiology (ESC),
May 17-20 at the Megaron Athens International Conference Centre in Athens,
Greece.

Additional information on the poster presentations can be found below and
posters can be accessed atwww.sunshineheart.comfollowing the presentations on
May 17th.

-----------------------------------------------------------------------------------------------------
| |
|Poster Presentations: |
|Date/Time: Saturday, May 17, 2014, 8:30 AM - 6:00 PM |
|Location: Poster Area |
|Session Title: Poster with discussant session |
|Presentation Title: Preliminary results from the C-Pulse® System European Multicenter Study |
|Authors: Holger Hotz, MD, Leonhard Bruch, MD, Jan Schmitto, MD, Thomas Krabatsch, MD |
|Abstract Number: P256 |
| |
|Date/Time: Saturday, May 17, 2014, 8:30 AM - 6:00 PM |
|Location: Poster Area |
|Session Title: Poster with discussant session |
|Presentation Title: Improvements in Myocardial Perfusion Observed in Patients Supported with the |
| C-Pulse® Counterpulsation Device |
|Authors: Renzo Cecere, MD, Marc Hickeson, MD, Nadia Giannetti, MD |
|Abstract Number: P260 |
| |
-----------------------------------------------------------------------------------------------------
About the C-Pulse®Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device
in the United States, Canada and countries that do not recognize the CE mark
approval, utilizes the scientific principles of intra-aortic balloon
counterpulsation applied in an extra-aortic approach to assist the left
ventricle by reducing the workload required to pump blood throughout the
body, while increasing blood flow to the coronary arteries. Combined, these
potential benefits may help sustain the patient's current condition or, in
some cases, reverse the heart failure process, thereby potentially preventing
the need for later-stage heart failure devices, such as left ventricular
assist devices (LVADs), artificial hearts or transplants. It may also provide
relief from the symptoms of Class III and ambulatory Class IV heart failure
and improve quality of life and cardiac function. Based on the results from
our feasibility study, we also believe that some patients treated with our
C-Pulse System will be able to stop using the device due to sustained
improvement in their condition as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to
Investigational use.

About Sunshine®Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company
focused on developing, manufacturing and commercializing the C-Pulse System
for treatment of Class III and ambulatory Class IV heart failure. Sunshine
Heart has completed an approved U.S. Food and Drug Administration (FDA)
feasibility clinical study of the C-Pulse System and presented the results in
November 2011. In March 2012, the FDA notified the Company that it could move
forward with an investigational device exemption (IDE) application. Sunshine
Heart received unconditional approval from the FDA in November 2012 to
initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark
approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware
corporation headquartered in Minneapolis with wholly owned subsidiaries in
Australia and Ireland. The Company has been listed on the NASDAQ Capital
Market since February 2012.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are
based on management's beliefs, assumptions, expectations, and information
currently available to management. All statements that address future
operating performance, events or developments that we expect or anticipate
will occur in the future are forward-looking statements, including, without
limitation, our expectations with respect to future clinical study activities
and results including patient enrollment in studies. These forward-looking
statements are subject to numerous risks and uncertainties, including,
without limitation, the possibility that our clinical studies do not meet
their enrollment goals, meet their endpoints or otherwise fail, that
regulatory authorities do not accept our application or approve the marketing
of the C-Pulse System, the possibility that we may be unable to raise the
funds necessary for the development and commercialization of our products,
that we may not be able to commercialize our products successfully in the EU
and the other risk factors described under the caption "Risk Factors" and
elsewhere in our filings with the SEC. You should not place undue reliance
on forward-looking statements because they speak only as of the date when
made and may turn out to be inaccurate. We do not assume any obligation to
publicly update or revise any forward-looking statements, whether as a result
of new information, future events or otherwise. We may not actually achieve
the plans, projections or expectations disclosed in forward-looking
statements, and actual results, developments or events could differ
materially from those disclosed in the forward-looking statements.

CONTACT: For further information, please contact:

Investor:
Candice Knoll
Blueprint Life Science Group
T: +1-415-375-3340 Ext. 105

Jeff Mathiesen
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200

Media:
David Schull
Russo Partners
T: +1-212-845-4271

Andreas Marathis
Russo Partners
T: +1-212-845-4235

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Sunshine Heart, Inc. via Globenewswire

HUG#1785222

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.